US 4072576

I'll search for any current USPTO records and CAFC 2026 docket activity involving US patent 4072576, then summarize.

Search results for US 4072576 (searches run 2026-04-26)

No CAFC 2026 docket or USPTO litigation activity was found for this patent number. My searches returned only unrelated 2026 Federal Circuit matters (e.g., Contour IP Holding LLC v. GoPro, Inc., Fed. Cir. No. 2026-2012) and unrelated PTAB hearings — none cite 4072576. This is consistent with the patent's status: Google Patents lists it as "Expired – Lifetime," anticipated expiration 1995-02-07, so it is long past term and cannot be asserted. Hits for "4072576" in other contexts (e.g., Argentine domain registrations) are unrelated numbers.

Caveat: My results come from general web search of patent aggregators (Google Patents, FreePatentsOnline, uspto.report, Justia), not a direct USPTO PatentCenter/CAFC docket query. I cannot confirm a negative docket result authoritatively; absence of CAFC hits is based on search only.

---

Bibliographic summary (per Google Patents text provided)

Uncertainty note: The "current assignee = Phadia AB" entry is Google's automated assignment metadata and reflects a later transfer of the Kabi/Pharmacia line; the patent as issued was assigned to Kabi AB. I have not independently verified the chain of title.

Abstract (as published)

"Method for studying biochemical reactions in which a substance, whose activity or concentration is to be determined, affects a substrate specific for the biochemical reaction which includes providing electrodes coated with the substrate, determining as the control value, the capacitance in a measuring device containing the electrodes, introducing the substance into the measuring device, measuring the change in capacitance, and thereby obtaining a quantitative measure of the activity or concentration of the substance present in the sample and affecting the specific substrate on the electrodes."

Independent claim — plain-language overview

Only claim 1 is independent. (Claims 2–16 all depend, directly or indirectly, on claim 1.) Per the authoritative text, claim 1 reads "activity of concentration" — I interpret the claim literally but read this as the apparent typo for "activity or concentration," as in the abstract.

Claim 1 — the core capacitive biosensing method:
An assay method for determining the activity or concentration of a biochemical substance in a sample, where that substance biochemically acts on a substrate specific to it, comprising four steps:

1. Provide coated electrodes — metallic or semiconductor electrodes coated with the specific substrate;
2. Establish a control value — measure the capacitance across those coated electrodes in the measuring device;
3. Add the sample so the coated electrodes contact it; and
4. Measure the capacitance change, where that change is due to a change in the amount of biochemically unaffected (i.e., still-intact) substrate coating the electrodes — the measured change giving a quantitative measure of the substance's activity or concentration.

Core inventive concept: transducing a biochemical reaction as a capacitance change at a substrate-coated metal (or semiconductor) electrode, without optics or labels — the ancestor of modern capacitive/impedimetric affinity biosensors.

Dependent claims (grouped)

• Sample/coating preparation (2–4): electrodes coated by immersion in a substrate solution that adsorbs onto the electrode surface (2); substrate molecules desorb/dissociate upon action of the substance (3); or the substrate-bound substance increases layer thickness (4).
• Apparatus (5): capacitance measured with an electric impedance bridge.
• Serine-protease embodiment (6–7): substance is a serine protease (thrombin/plasmin/trypsin) and substrate is a synthetic splittable polypeptide (6); claim 7 defines a specific chromogenic peptide substrate formula with variables R¹–R⁵ and n = 3 or 4 (the formula is rendered as "##STR1##" in the retrieved text).
• Binding-pair embodiment (8–9): substrate molecules are inhibitors (8) or receptors for hormones (9).
• General/substance type (10): the biochemical substance is an enzyme.
• Electrode material (11–14): metallic electrodes (11); selected from platinum, copper, silver, molybdenum, titanium, gold, palladium, nickel chrome (12); platinum (13); monomolecular-layer coating (14).
• Coating mode (15–16): substrate chemically bound to the electrode (15); electrode surface not entirely saturated with substrate (16).

Key prior art cited

US 3,275,534 (Cannon, bioelectric anti-cholinesterase detection); US 3,479,255 (Beckman electrochemical transducer); US 3,635,681 (Miles, differential conductivity); and US 3,884,896 (Bofors AB) — the chromogenic polypeptide substrate whose formula the patent expressly reuses.

Note: This patent underlies broad downstream art; Google Patents lists ~119–292 forward citations, including the Affymetrix photolithographic arrays and Molecular Devices capacitance-detection lines.

I'll search for litigation records involving US patent 4072576.

Let me search more targeted sources for this specific patent number.

Litigation Search: US Patent 4,072,576

Bottom line

No litigation involving U.S. Patent No. 4,072,576 is known to me, and I found none in searching. I want to be explicit about the limits of that statement, because there are two distinct reasons a "no results" answer can arise here:

1. Genuinely no cases exist (plausible), and
2. Cases may exist but are not indexed in modern databases (a real risk for this patent).

---

The specific patent at issue (confirmed, not assumed)

Before answering, I verified that the identifier "4072576" as used maps to the correct document and did not auto-correct it:

Sources: Google Patents US4072576A; uspto.report/patent/grant/4072576; FreePatentsOnline/4072576.

Note one procedural item that could reflect a dispute-adjacent event: uspto.report flags that images exist for a "Certificate of Correction" on this grant. A certificate of correction is a routine USPTO clerical/assignee fix, not evidence of litigation, and I did not find its contents.

---

Searches performed and results

I searched litigation-oriented sources (Unified Patents portal references, CourtListener/RECAP, Justia, Docket Alarm, federal court opinions, and general web) for the exact identifier. Every apparent hit was for a different patent whose number ends in the same four digits. I did not merge these; listing the near-misses is important precisely so the record is clean:

I state plainly: none of the above involves US 4,072,576, and I have not attributed any of them to it.

---

Why an absence of results is credible here — and where it is uncertain

Supporting "no litigation":

• The patent expired February 7, 1995. Any infringement suit would have had to be filed roughly between 1978 and the mid-1990s. It would not appear in the modern NPE/PTAB-era litigation portals that dominate search results (the Unified Patents caselist and most IPR feeds begin well after 2012).
• The record shows no IPR, PGR, CBM, or reexamination challenge — unsurprising, since the AIA post-grant proceedings did not exist during this patent's life, and the patent was long expired before they did.
• The accused-art context (its own specification cites only academic literature — Gough & Andrade, Rothen, Lawrence & Moores, Bockris & Reddy — and U.S. Pat. No. 3,884,896 to Bofors AB) suggests a research-stage assay method, not a commercially enforced product claim.

Where I am genuinely uncertain (I will not paper over this):

• Pre-1995 federal patent cases for this era are poorly digitized. PACER's electronic case data generally does not reach back to the late 1970s and 1980s, so a suit filed in, say, 1980–1990 would likely be invisible to the searches I can run. I therefore cannot represent that no suit was ever filed during the patent's enforceable life.
• I did not have a functioning, direct query against the exact Unified Patents litigation caselist URL or a live PACER docket lookup for this number within my search steps; my conclusion rests on secondary aggregators (CourtListener/RECAP, Justia, Docket Alarm, Google Patents' litigation section, which showed no entries).

---

What I can and cannot give you per the requested fields

Because no case was found, the requested table (plaintiff / defendant / jurisdiction / case number / filing date / outcome) cannot be populated for this patent. I am not going to manufacture case numbers or parties to fill the format.

If you need a definitive answer, the following would settle it, and I did not complete them:

1. A direct search of the USPTO Patent Assignment and litigation-history databases and the USPTO's "Patent Litigation Docket" / Patent Examination Data for Patent No. 4,072,576 (which lists district court actions where the patent was asserted).
2. A PACER "Case Locator" (national index) search by patent number, which can surface older cases that CourtListener's RECAP archive lacks.
3. Contacting the current assignee, Phadia AB (successor to Kabi AB), and checking Kabi/Pharmacia historical litigation disclosures, since any 1978–1995 enforcement would most likely have been brought by that corporate family.

Summary

• US 4,072,576 litigation found: none.
• Confidence: moderate-to-high that no modern litigation exists; low that no historical (1978–1995) litigation exists, solely due to pre-PACER record gaps.
• Caution flag: the many search hits styled "the '576 patent" belong to different patents and must not be attributed to US 4,072,576.

Proceedings overview

There are zero AIA trial proceedings on file for US 4,072,576 — no IPR, no PGR, no CBM — and therefore no institution decisions, final written decisions, settlements, or Federal Circuit appeals arising from an AIA trial. This is the canonical answer from the structured USPTO Open Data Portal block supplied for this patent ("The USPTO ODP API returns no AIA trial proceedings for this patent as of the most recent ingest"), and it is corroborated by my searches of Google Patents' proceeding data, PTAB petition/decision repositories, and the published PTAB hearing schedules covering 2026-03 through 2026-06. No proceeding number on any of those sources identifies US 4,072,576 as the challenged patent, and no invented proceeding number appears in this report.

The defensive posture this produces is the strongest one possible for a defendant, but for an unusual reason: the "hardened patent" framing does not apply, and neither does the "claims canceled in IPR" framing. The bottom line is that no AIA trial is possible or worthwhile here, because the patent is a 1975-priority, 1978-grant, long-expired patent whose entire statutory term ended in the 1990s. If a demand letter or a complaint cites US 4,072,576, the defect is not an IPR outcome — it is Article III standing and patent term.

Why the AIA pathways are structurally unavailable

No proceedings to report. There is no petitioner/patent-owner caption, no panel, no grounds, no institution decision, no FWD, no termination, and no appeal. I am not going to manufacture those fields for a proceeding that does not exist.

False-positive warning — the "'576 patent" collision

Every apparently on-point hit I found for a "'576 patent" in PTAB or district-court materials refers to a completely different patent that happens to share the last three digits:

• The Entropic Communications v. DIRECTV/DISH matters (e.g., C.D. Cal. 2:22-cv-07775-JWH-KES) concern a "'576 patent" claiming satellite transponder signal selection/extraction, and a September 2023 PTAB institution denial addressing the Williams/Pugel combination — not US 4,072,576. (C.D. Cal. Dkt. 295)
• The ContentGuard IPR and claim-construction materials referencing a "'576 Patent" concern a digital-rights-management repository patent — again not this one. (contentguard claim construction order)

Anyone doing a naive string search on "4072576" or "'576" and pulling these into an IPR diligence memo would be citing irrelevant art. Do not let that happen in a motion or an invalidity contention.

Proceedings by claim outcome

Strategic summary

Claim landscape. Because no AIA trial exists, the operative facts about the claims are the ones in the earlier sections: claim 1 is the sole independent claim, claims 2–16 depend from it, and all 16 claims stand exactly as granted in 1978, unamended. There is no narrowing certificate, no certificate of correction that I can identify, and no IPR certificate to point to. For an accused infringer this cuts both ways in the abstract — you cannot say "the claims are already dead at the Board," but you also face claims that were drafted in an era when § 112 written-description and § 103 obviousness doctrine looked very different, and whose claim 1 contains a plainly facially defective recitation ("activity of concentration," per the authoritative text, versus "activity or concentration" in the abstract and specification). That defect is an indefiniteness/enablement argument for a district court, not an IPR ground.

Estoppel landscape. No § 315(e)(2) estoppel attaches to anyone, from any direction. Because no IPR or PGR was ever instituted, no petitioner, real party in interest, or privy has been estopped from raising any ground — raised or reasonably raisable — in a civil action or before the Office. There is no SAS-instituted trial, no partial institution, and no FWD to trigger estoppel. Practically: the entire prior-art universe remains available to a defendant, including the four references cited on the face of the patent (US 3,275,534 Cannon; US 3,479,255 Beckman; US 3,635,681 Miles; US 3,884,896 Bofors) plus the family-cited art (FR 1,479,929; US 3,694,163; CH 524,142; US 3,757,210), plus the non-patent literature the patent itself admits — Gough & Andrade, Science 180:380–384; Rothen, Physiol. Chem. & Physics 5 (1973); Lawrence & Moores, Eur. J. Biochem. 24:538–546 (1972); and Bockris & Reddy, Modern Electrochemistry Vol. 2, ch. 7. That admission-heavy specification is unusually fertile § 102/§ 103 ground.

Pattern signals. There is nothing to pattern-match: no repeat petitioner, no defensive aggregator (no Unified Patents or similar filing appears in the record for this patent), and no patent-owner appellate strategy, because there was never a trial to appeal. The asymmetry with the earlier section's finding of no 2026 CAFC docket activity is fully consistent — a party cannot appeal an FWD that was never issued (35 U.S.C. § 319 appeal rights run from an FWD), so the absence of CAFC activity is a consequence of the absence of PTAB activity, not independent evidence.

One correction/flag on the prior section. The earlier bibliographic summary states the anticipated expiration as 1995-02-07, sourced from Google's metadata (17 years from the 1978-02-07 grant). That date is right under the pre-URAA 17-year measure, but Google's "anticipated expiration" is a heuristic. Under the URAA transitional rule, 35 U.S.C. § 154(c)(1), a patent resulting from an application filed before 1995-06-08 receives the greater of 17 years from grant or 20 years from the US filing date — i.e., potentially 1996-09-20. Since Google reports the status as "Expired – Lifetime" rather than "Expired – Fee Related," the maintenance fees at 3.5, 7.5, and 11.5 years presumably were paid, so the statutory term — not a fee lapse — is what ended it. Either way the patent has been expired for roughly thirty years, and nothing in this analysis turns on the one-year discrepancy. I flag it so no one repeats the 1995 date as if it were adjudicated.

Recommended next steps

1. Say it plainly in your invalidity/standing memo: there is no PTAB proceeding to cite. Do not build a defense narrative around an IPR that does not exist. The correct first-line response to any assertion of US 4,072,576 is that the patent's term expired in the 1990s (1995-02-07 per the Google record; possibly 1996-09-20 under § 154(c)(1)) and that no infringement can accrue from post-term conduct. Confirm the exact expiration date against the USPTO Patent Center "Application Data" / "Patent Term Adjustments" and the fee-payment history at patentcenter.uspto.gov before filing anything that turns on the date.

2. Verify the negative through the primary source rather than search. Query Patent Trial and Appeal Board End-to-End (PTAB E2E) at ptacts.uspto.gov/ptabweb by patent number, and cross-check the ODP PTAB API at developer.uspto.gov/api-catalog. My searches are a search-based negative; the E2E docket query is the authoritative one, and it is cheap to run.

3. If you are a defendant facing a live assertion, the useful defenses are not PTAB defenses. They are: (a) the patent's expired term; (b) § 102/§ 103 over the four cited references and the specification's own admitted prior art; (c) § 112 indefiniteness as to claim 1's "activity of concentration" and the "##STR1##" Markush variables R¹–R⁵ in claim 7, whose boundaries were never construed; and (d) the absence of any post-1995 damages period.

4. Do not draft around the "'576 patent" false positives. If opposing counsel or a prior art vendor hands you PTAB materials captioned with a "'576 patent," confirm the full eight-digit number before relying on them. The Entropic and ContentGuard materials are unrelated to US 4,072,576.

I'll attempt to pull assignment records before writing anything. Let me run several searches.

No assignment data yet. Let me probe the ownership chain and Google Patents legal events directly.

Let me make two final targeted attempts at reel/frame-level records.

I was unable to retrieve any reel/frame-level assignment records for this patent. Here is the analysis, with that limitation stated up front.

---

Research limitation (read first)

The brief specifies USPTO Patent Assignment Search at assignmentcenter.uspto.gov (with the legacy index at assignment.uspto.gov/patent/index.html) as the primary source. In this session I had only general web-search access, not a live query against the Assignment Center. My searches for 4072576 + assignment terms returned: the patent text itself (Google Patents, FreePatentsOnline, SumoBrain, uspto.report), the OMB clearance package describing the Assignment Center user interface (which confirms the new system's fields — conveyance type, conveying/receiving party, correspondent first/last name, mailing address, email — but contains no records), and unrelated patents' file histories. No reel/frame number, no conveyance type, no assignor/assignee record, and no correspondent of record for US 4072576 were retrievable.

I am therefore reporting a negative search result, not a verified negative Assignment Center result. I will not synthesize reel/frame numbers to fill the template.

---

Inventors

The issued US patent names Kabi AB as assignee (Google Patents "Original Assignee"; FreePatentsOnline renders it "AB Kabi"). Because the inventors are named personally on the face of the patent while the assignee is a corporation, the standard inference is that both inventors executed an assignment to Kabi AB at or before filing (an employment or contract-research assignment). That inference is not up to date — I could not retrieve the recording.

Affiliation note, hedged deliberately: the surnames Arwin and Lundström recur in the Swedish sensor-research milieu (Linköping University applied-physics / biosensor community) contemporaneous with and after this filing. I cannot confirm that either inventor held a Linköping affiliation at the 1975 filing date, and I will not assert it as fact. What the record does establish is that the applicant of record was Kabi AB, a Stockholm-based pharmaceutical company (not a university), so the inventors' work here was routed through Kabi.

Unusual-pattern check (inventor departure within 12 months → fire-sale precursor): Cannot be assessed — no assignment or personnel records were retrievable. Nothing in the searchable record suggests an early inventor exit.

---

Original assignee

Kabi AB (rendered "AB Kabi" on the patent and FreePatentsOnline; Google Patents lists "Kabi AB"), Stockholm, Sweden.

• Primary line of business: Swedish pharmaceutical company, founded 1931. Its relevance here is the coagulation / blood-protein diagnostics line — the patent's own background section frames the invention's clinical use case as "clinical test of for instance the amounts of antithrombin and prothrombin," and the substrate relied upon is the chromogenic peptide of US 3,884,896 (Bofors AB), a Swedish diagnostics rival. Kabi was a genuine operating company in this space, not a holding entity.
• Did they ship a product embodying the claims? No evidence found. The patent's own text describes an impedance-bridge laboratory method, and the specification admits the substrate used was "by no means optimal for the electric detection which has been described." I found no Kabi/Pharmacia/Phadia capacitive-assay instrument in commerce. The successor Phadia went to market with its ImmunoCAP platform, which is a fluorescent enzyme immunoassay, not a capacitive/impedimetric readout — so I have no basis to say the claims were commercialized in the product line that inherited the corporate identity.
• Current status: Operating, but not as Kabi. Kabi is not an independent entity today. Corporate lineage (from Swedish/Wikipedia/archive-of-Pharmacia-diagnostics.com sources): Kabi merged with Vitrum → Kabi Pharmacia (1990) → renamed Pharmacia (1993) → merged with Upjohn (1995) → Pharmacia & Upjohn → merged with Monsanto, renamed Pharmacia Corporation (1999) → acquired by Pfizer (announced 2002/closed 2003) → the Uppsala diagnostics division sold to private equity (PPM and Triton, 2004) → renamed Phadia AB (16 January 2006) → acquired by Thermo Fisher Scientific (2011). Separately, the drug business acquired by Pharmacia & Upjohn became Fresenius Kabi. None of this lineage is a bankruptcy; the diagnostics unit moved by divestiture and change of name, not Chapter 7/11.

Cross-reference to the earlier section — flagging a possible contradiction: the earlier bibliographic summary correctly noted Google's "Current assignee = Phadia AB" as automated assignment metadata reflecting a later transfer of the Kabi/Pharmacia line, with the chain of title unverified. My independent searching corroborates the Phadia AB identity and the 2006 name change and the 2011 Thermo Fisher acquisition, but still cannot confirm that any of these events was recorded against US 4072576 specifically. If the Phadia line does hold title, the practical owner today would be a Thermo Fisher Scientific entity — but note the patent's anticipated expiration was 1995-02-07, i.e. six years before Phadia even existed as a name, so any post-2006 recordation would be a bookkeeping carry-over of a spent asset.

---

Assignment timeline

Plainly stated: I found no verifiable recorded assignment for US 4072576. No reel/frame, conveyance type, assignor/assignee pair, execution date, recording date, or correspondent of record could be retrieved.

Per the task protocol, that is itself the finding: the retrievable record stops at the original issuance to Kabi AB (granted 1978-02-07, priority 1975-10-06, filed 1976-09-20). What I can add is non-record corporate context, clearly quarantined below.

Non-record corporate context (NOT USPTO assignment records — do not cite as reel/frame evidence): the Kabi → Kabi Pharmacia → Pharmacia → Pharmacia & Upjohn → Pharmacia Corp → Pfizer → Pharmacia Diagnostics → Phadia AB → Thermo Fisher lineage documented in the "Original assignee" section. Any of these steps, if recorded at all against this patent, would most plausibly have appeared as Merger or Change of Name conveyances rather than asset assignments. I could not confirm even that.

---

Timeline diagram

Caution: the block below renders unverified corporate lineage, not recorded assignments. I am including it only because the corporate facts are independently sourced; treat every node as context, not as a reel/frame finding.

timeline
    title Contextual lineage for US 4072576 not verified assignment records
    1975 : Swedish priority filed by Kabi
    1976 : US application filed
    1978 : US 4072576 granted to Kabi AB
    1990 : Kabi merges with Pharmacia
    1993 : Company renamed Pharmacia
    1995 : Patent term ends
         : Pharmacia merges with Upjohn
    1999 : Monsanto deal forms Pharmacia Corp
    2003 : Pfizer acquires Pharmacia
    2004 : Diagnostics unit sold to private equity
    2006 : Renamed Phadia AB
    2011 : Thermo Fisher acquires Phadia

---

NPE / troll-pattern signals

---

Verdict

Insufficient data (no records, or only the original assignment).

Justification: the retrievable record contains no recorded post-issuance assignment — no reel/frame, no conveyance type, no correspondent — for US 4072576, so the shell-entity, cascading-transfer, repeat-correspondent, and pre-litigation signals cannot be scored at all; and of the signals that can be scored, every one resolves negative, most decisively because the patent's anticipated expiration of 1995-02-07 predates every NPE-era transfer market and forecloses assertion (no infringement suit, no CAFC docket activity — corroborating the earlier section). The only affirmative ownership facts are the original issuance to Kabi AB (granted 1978-02-07, priority 1975-10-06) and the general Kabi → Pharmacia → Pfizer → Phadia AB → Thermo Fisher corporate lineage, none of which I could tie to a recorded filing in this patent's chain of title.

Verification link: https://assignmentcenter.uspto.gov/ (search the patent number 4072576; legacy index at https://assignment.uspto.gov/patent/index.html). A live PatentCenter/Assignment Center query is required to convert this "insufficient data" call into a definitive one — specifically the correspondent of record on any Merger / Change of Name entry, which is the one datum that would let this analysis be completed as the brief envisions.

I'll ground this in live searches — both for the patent record and for each cited reference — before analyzing anticipation.

Now let me verify the remaining cited references and the family-level cites.

Prior Art Analysis — US 4,072,576 A

"Method for studying enzymatic and other biochemical reactions"
Inventors: Hans R. Arwin; Kurt I. Lundström | Original assignee: Kabi AB | Priority 1975‑10‑06 (SE 7511148) | U.S. filing 1976‑09‑20 | Granted 1978‑02‑07.

Per the operating rules, I take the authoritative patent text supplied (Google Patents, https://patents.google.com/patent/US4072576/en) as controlling over search results where they conflict. All identifiers below are reproduced literally.

---

1. How I scoped "each patent citation for 4072576"

The Google Patents record for US 4,072,576 lists two distinct citation sets, which must not be conflated:

Everything in § 2 below is a direct citation of record. None of the four is a § 102 anticipating reference against claim 1, for reasons given per reference — but they map onto identifiable claim elements, which I flag.

Note on the "Cited By (119/292)" list: those are forward citations (later patents citing 4,072,576, e.g., Affymetrix's US 5,143,854 and Molecular Devices' capacitance art). They are not prior art and are excluded.

---

2. The four Patent Citations of record — full analysis

2.1 US 3,275,534 A — Cannon, Jr., Paul L.

• Title: "Bioelectric method for the detection of anticholinester‑ases"
• Priority/filing: 1963‑03‑19 · Granted: 1966‑09‑27
• § 102 status: published >1 yr before the 1976‑09‑20 filing → pre‑AIA § 102(b) art (foreign priority cannot antedate it, In re Hilmer).

Description (from the patent PDF): A bioelectric method in which a DC current is applied across two platinum electrodes immersed in a buffered, neutral aqueous solution of an anticholinesterase agent and a thiocholine ester, with a reference half‑cell (calomel). Cholinesterase is then added; the potential between the positive electrode and the reference electrode is recorded as a function of time, and the "potential change per unit of time is the rate of depolarization of the positive electrode" — calibrated to read µg of agent. (https://patentimages.storage.googleapis.com/7e/1f/7c/478092978d3add/US3275534.pdf)

Anticipation analysis:

• Shares: platinum working electrodes; an enzyme–substrate reaction occurring at the electrode surface; and the readout of rate of change per unit time as a measure of activity — conceptually parallel to the "change of capacitance per time unit" of claim 1.
• Fatal gap: it measures electrode potential (depolarization), not capacitance, and there is no "control capacitance" step and no coated-substrate electrode. It therefore cannot anticipate claim 1 (which requires measuring the change in capacitance).
• Claim mapping: discloses only background elements → arguably relevant to claim 10 (substance is an enzyme: cholinesterase), claim 11/13 (platinum electrodes). As these claims depend on claim 1, US 3,275,534 does not anticipate any claim. A reference disclosing a sub‑combination cannot anticipate a claim requiring more.

---

2.2 US 3,479,255 A — Beckman Instruments, Inc.

• Title: "Electrochemical transducer" (inventor: Edwin P. Arthur)
• Filing: 1964‑01‑27 · Granted: 1969‑11‑18
• § 102 status: pre‑AIA § 102(b).

Description: An electrochemical ion‑sensing transducer: a body with an electrode face, a selectively permeable membrane clamped over the end to define an electrolyte film space, and a passage for electrolyte flow between electrode and membrane; the ionic concentration of a sample reacting at the membrane is measured by the electrode half‑cell. (https://SumoBrain.com/patents/us/Electrochemical-transducer/[3479255](/patent/3479255).html)

Anticipation analysis:

• Shares: nothing structural with claim 1 beyond "an electrode in a measuring apparatus."
• Fatal gap: it is a potentiometric ion/membrane sensor — no capacitance, no substrate-coated electrode, no enzyme‑substrate layer whose amount changes. It measures an ion concentration via a membrane‑separated electrolyte, an entirely different transduction mechanism.
• Claim mapping: arguably generic background for claim 5 (an electrical measuring circuit in a measuring device) and claim 11 (electrode). Anticipates no claim.

---

2.3 US 3,635,681 A — Miles Laboratories, Inc.

• Title: "Differential conductivity‑measuring apparatus"
• Filing: 1969‑11‑13 · Granted: 1972‑01‑18
• § 102 status: pre‑AIA § 102(b).

Description: Apparatus with two probes, each a pair of spaced electrodes. The first probe's electrodes carry a test reagent (e.g., an enzyme) immobilized in a matrix; the second probe is a reference. When both probes contact an ionic medium containing the substance to be detected, the circuit subtracts the background conductivity and continuously measures the change and rate of change of conductivity produced by the enzyme–substrate reaction as a measure of the substance. (https://patents.google.com/patent/US3635681; https://patentimages.storage.googleapis.com/1a/46/d1/6e33bcb44f176/US3635681.pdf — PDF ID as listed)

Anticipation analysis — this is the closest of the four:

• Shares several conceptual pillars of claim 1: (i) an electrode pair bearing a reagent; (ii) electrical measurement of a change produced by a biochemical reaction at the electrode; (iii) an explicit control/background subtraction step (cf. claim 1's "control value" determination); and (iv) rate‑of‑change output as a quantitative measure of the substance — cf. claim 1's "change of capacitance per time unit."
• Fatal gaps (three):
  1. The measured quantity is conductivity/resistance, not capacitance ("change and rate of change in electrical conductivity").
  2. The reagent is the immobilized species (enzyme in a matrix) and the analyte is the substance to be detected in solution — the inverse of claim 1, where the substrate is the electrode coating and the biochemical substance is introduced from the sample.
  3. No teaching that the reagent is adsorbed/desorbed or that layer thickness on the electrode changes.
• Claim mapping: closest to the generic concept of claim 1 and to claim 5 (electrical measuring circuit) — but claim 5 expressly recites an impedance bridge, and US 3,635,681 uses audio‑frequency conductivity bridge/amplifier circuits, not an impedance bridge. Anticipates no claim. At most it is a strong § 103 candidate against the "measure electrical change as a function of time" concept.

---

2.4 US 3,884,896 A — AB Bofors

• Title: "New substrates for diagnostic use, with high susceptibility to thrombin and other proteolytic enzymes"
• Priority: 1972‑05‑02 · Granted: 1975‑05‑20 (listed inventor: Blombäck, per secondary source)
• § 102 status: granted 1975‑05‑20, i.e. more than one year before the 1976‑09‑20 filing → pre‑AIA § 102(b).

Description: Chromogenic amide/peptide substrates for proteolytic enzymes of the peptide‑peptidohydrolase type (thrombin, plasmin, trypsin), hydrolyzed to give a chromophoric product measurable spectrophotometrically. The disclosure recites a general formula with substituent variables R₁–R₅ and n = 2, 3 or 4 — the same genus the present patent's claim 7 imports ("R₁ is … Nα‑benzoyl‑phenylalanyl; R₂ is phenyl, benzyl, 4‑hydroxy‑benzyl …; n is 3 or 4"). (https://patents.google.com/patent/[US3884896A](/patent/US3884896A))

Anticipation analysis — the key point:

• This is the source of the substrate chemistry, and the present specification expressly says so: the substrate "consists of a polypeptide of the type described in the U.S. Pat. No. 3,884,896." Claim 7 of 4,072,576 sets out that substrate genus.
• However, US 3,884,896 discloses the substrate per se plus its optical (spectrophotometric) use. It contains no capacitance measurement, no coated electrode, no control‑capacitance step. As a § 102 reference it cannot anticipate claim 7 (a method claim), because claim 7 requires the capacitive method steps of claim 1 plus the recited substrate.
• Claim mapping: substantively discloses the substrate element recited in claims 6 and 7 (serine‑protease‑splittable synthetic polypeptide; the specific formula). Relevant as a § 103 secondary reference (substrate selection), not an anticipating reference.

---

3. Family‑level citations (foreign counterparts) — lower confidence

These four appear in the "Family Cites Families" field (i.e., cited on foreign family members), not on the U.S. case. I was unable to re‑verify them live in this session (search step limit reached), so I report only what the supplied record states and flag the uncertainty.

Anticipation analysis: FR 1,479,929 and the two Miles references are electrochemical/enzymatic analysis art and, like the U.S. citations, measure potential/conductivity/optical signals — none is a substrate‑coated‑electrode capacitance method, so none appears to anticipate claim 1. I cannot state their content with confidence because I did not re‑access them; treat this as a to‑verify list.

---

4. Non‑patent literature cited in the specification (context, not patent citations)

The specification cites these as known art (all pre‑date the 1975 priority):

• Gough & Andrade, "Enzyme Electrodes," Science Vol. 180, pp. 380–384 — the "enzyme electrode" (membrane‑potential) approach the inventors distinguish.
• Rothen, "Immunologic and enzymatic reactions carried out at a solid‑liquid interface," Physiol. Chem. & Physics 5, 1973 — ellipsometric layer‑thickness measurement on nickel‑metallized glass; the optical analogue the invention seeks to replace.
• Lawrence & Moores, "Conductometry in Enzyme Studies," Eur. J. Biochem. 24 (1972) 538–546 — conductometric enzyme assay.
• Bockris & Reddy, Modern Electrochemistry, Plenum Press, Vol. 2, ch. 7 — organic molecules adsorb on electrodes and change their electrical properties (the physical premise of the invention).

These are the references a § 103 obviousness case would most plausibly be built on (conductometry + adsorption‑changes‑electrode‑properties), but again none discloses capacitive transduction of a coated substrate.

---

5. Bottom line on anticipation under 35 U.S.C. § 102

Findings:

1. No cited reference anticipates claim 1 or any dependent claim under § 102. Each of the four misses at least one element of claim 1 — most decisively, none measures capacitance, and none discloses a substrate coating on the electrodes whose amount changes as the measured variable. The inventive core of claim 1 (transducing the substrate–substance reaction as an electrode capacitance change, with a control‑capacitance baseline) is not met by any of them.
2. US 3,635,681 is the most relevant single reference — it is the only citation that combines electrodes, a biochemical reagent, background/control subtraction, and rate‑of‑change readout. Its conductivity (not capacitance) measurement and inverted reagent/analyte configuration keep it out of § 102, but it is the natural primary reference for any § 103 attack.
3. US 3,884,896 is the relevant reference for the substrate‑defining claims (6 and 7) — it is the express source of the polypeptide genus. It anticipates neither claim, since both are method claims incorporating the capacitive method of claim 1; but it would support the position that the substrate limitation was old in the art, leaving the capacitive method as the point of novelty.
4. US 3,275,534 is the relevant reference for the "activity/rate" and platinum‑electrode features (claims 10, 11, 13), and is the closest to the "rate of change per time unit as a measure of activity" concept — but its signal is potential, not capacitance.

---

6. Caveats (stated explicitly, per the operating rules)

• Legal status of the patent is irrelevant to this § 102 exercise. US 4,072,576 is listed "Expired – Lifetime" (anticipated expiration 1995‑02‑07), so no § 102/§ 103 analysis has present‑day validity consequence; this is a historical/technical assessment.
• Family‑level citations (§ 3) are not re‑verified. I could not complete live retrieval of FR 1,479,929, US 3,694,163, CH 524,142, or US 3,757,210 in this session, and the last named (US 3,757,210, Betz) is described from a truncated title. I did not fabricate their contents; the "anticipates: No" assessment for them rests on their recorded titles/assignees and the fact that no capacitance‑based coated‑electrode method appears among them. They should be pulled and read directly before being relied upon.
• One identifier-tracking note: the US3635681 PDF URL returned in search (…6e33bcb44f176…) appears truncated relative to its true file path; I have not treated the URL text as a substantive document identifier, and the content I analyze is that returned by the Google Patents and FreePatentsOnline record pages for US 3,635,681, which agree.
• No new citation set was found. The user‑supplied Google Patents text lists exactly four patent citations of record; my searches did not surface additional § 102 references beyond the four (the "Similar Documents," "Cited By," and "Applications Claiming Priority" fields are, respectively, related art, forward citations, and family members — none prior art).

I'll ground this analysis by verifying the character of each cited reference, since § 103 reasoning turns on what each reference actually teaches.

Let me verify a few legal and non-patent-literature anchors before finalizing the § 103 reasoning.

Obviousness Analysis — U.S. Patent No. 4,072,576 under 35 U.S.C. § 103

Analyst note / flag before we begin: There is a date inconsistency in my instructions. The system header states today is 2026-09-27, while this task states 2026-04-26, and the previously generated summary section says its searches were run 2026-04-26. I have not reconciled these and note the discrepancy rather than silently picking one. Also, per the standing rule, I have used the identifier 4072576 / US 4,072,576 literally throughout without correction.

Update to the earlier sections: The "Key prior art cited" block in the earlier summary listed only titles of the four cited U.S. references. I have now retrieved their substance. That substance materially strengthens the prima facie § 103 case relative to what the titles alone conveyed — particularly US 3,635,681 (Miles), which teaches the electrode-immobilized-reagent + rate-of-change architecture almost point for point. This is a substantive upgrade, not a contradiction, of the earlier section.

---

1. Governing framework and critical date

Antedating: Every reference on the cited-art list predates the 1975-10-06 priority date. The closest is US 3,884,896 (Bofors AB), granted 1975-05-20 — about 4½ months before the priority date, so it is prior art under pre-AIA § 102(a) even against the foreign priority date (and separately under § 102(b) measured against the 1976-09-20 U.S. filing date). No 102(b) "critical date" problem arises for any reference.

Analogous art: All cited references — patent and non-patent — are drawn from electrochemical analysis of biochemical reactions, enzyme assay chemistry, or interfacial electrochemistry. There is no "non-analogous art" defense available; all references are from the field of the inventor's endeavor and are reasonably pertinent to the problem the specification itself identifies.

---

2. What claim 1 actually requires, and the delta over the art

Claim 1 (the sole independent claim) requires, in substance:

1. a method for determining activity/concentration of a biochemical substance that acts on a specific substrate;
2. metallic or semiconductor electrodes coated with that substrate;
3. a control capacitance measurement;
4. introduction of the sample into contact with the coated electrodes;
5. measurement of the capacitance change attributable to a change in the amount of unaffected substrate remaining on the electrodes;
6. the change being a quantitative measure.

The single element for which I find no literal disclosure in any cited reference is step (5)'s choice of capacitance as the transduced variable in an electrode-mounted-substrate enzyme/binding assay. Everything else — coated electrodes, electrode-immobilized reagent, a control/background reading, contact with sample, and the Δ-per-time or total Δ as the quantifier — is squarely disclosed, much of it in a single reference.

---

3. The prior art, characterized (grounded)

3.1 US 3,884,896 A — Blombäck et al., Bofors AB (granted 1975-05-20)

patents.google.com/patent/US3884896A · PDF

• Discloses the same synthetically splittable chromogenic peptide substrate genus recited in claim 7 of the patent at bar: R¹ acyl/sulfonyl variants, R² (phenyl, benzyl, 4-hydroxybenzyl, 4-methoxybenzyl, 4-methylbenzyl), R³ (straight/branched/cyclic alkyl C3–8, phenyl, benzyl), R⁴ (hydrogen or guanyl), R⁵ chromophore (phenyl, nitrophenyl, methylnitrophenyl, dinitrophenyl, naphthyl, nitronaphthyl, quinolyl, nitroquinolyl), with n selected from 2, 3 and 4.
• Expressly frames its utility as: "quantitative determination of ... enzymes of the type E.C. 3.4.4., especially such that break down peptides or proteins ... at the carboxylic side of arginine or lysine; e.g., thrombin, trypsin, plasmin" — i.e., the serine proteases of claim 6.
• Expressly states the substrates "may further be used for the study of reactions in which such enzymes are formed, inhibited or consumed, and also for the determination of factors which affect or participate in such reactions, for example the determination of proenzymes, activators, antienzymes and enzyme inhibitors." This is a direct textual predicate for claim 8 (inhibitor "substrate" molecules) and for the antienzyme/antithrombin arithmetic the specification of '576 describes.
• Its stated motivations are important to § 103: earlier amide substrates "do not possess the desired specificity and sensitivity," requiring "a considerable amount of biological material," with "long" reaction times and "unsatisfactory" precision. A POSA reading '896 is therefore expressly looking for a better readout of the same chemistry.

3.2 US 3,275,534 A — Cannon, Jr. (granted 1966-09-27)

PDF

• Applies direct current across two platinum electrodes immersed in a buffered, near-neutral solution containing a thiocholine-ester substrate, hydrolyzed by cholinesterase.
• Records an electrical quantity (potential/anode depolarization) as a function of time; "This potential change per unit of time is the rate of depolarization" — and calibrates it to give the amount of analyte.
• Critically, the reference motivates itself against optics: it is "a distinct improvement over this patented [colorimetric indophenol] method since it gives a quantitative indication ... and is not interfered with by extraneous colored solutions."

That last sentence is, functionally, the '576 specification's own stated motivation (turbid blood; plasma/serum required) appearing eighteen years earlier in the cited art.

3.3 US 3,635,681 A — Miles Laboratories (granted 1972-01-18)

patents.google.com/patent/US3635681 · FreePatentsOnline

This is the most probative reference and warrants verbatim attention:

• "a pair of probes each of which has a pair of electrodes, the electrodes of one of said probes having the test reagent associated therewith by matrix means, preferably in fixed form, such that when said probes are placed in contact with an ionic medium containing the substance to be detected, the conductivity between the electrodes is dependent upon ... the reagent and/or said ionic medium" (abstract).
• The electrodes of the first probe are "in intimate contact with a test reagent, such as an enzyme, incorporated with a matrix means"; the second probe acts as the control/reference channel.
• The apparatus "electronically subtracts the background conductivity" and includes "a differentiator circuit ... to measure the change and rate of change in conductivity."
• It expressly addresses enzyme–substrate reactions and the analytic problem of continuous measurement, and criticizes the earlier art (US 3,421,982) for requiring continuous manual adjustment and for assuming linearity.

Element-by-element, Miles '681 discloses: electrodes bearing an immobilized reagent; contact with a sample medium containing the counterpart reactant; a control measurement taken from a reference electrode pair; and Δ-per-time or total Δ as the readout. The only material difference is which electrical property is transduced (conductivity vs. capacitance), and which partner is on the electrode (in '681 the enzyme; in '576 the substrate).

3.4 US 3,479,255 A — Beckman Instruments (granted 1969-11-18)

SumoBrain record

An electrochemical transducer for clinical/analytical measurement — an ion-sensing electrode with a selectively permeable membrane, electrical output as rate or equilibrium condition. No coating, no capacitance. Its § 103 role is corroborative: it establishes that electrode-based electrochemical transduction of a biochemical reaction was a mature, well-explored design space by 1969, and that "electrode + membrane-mounted recognition layer + electrical output" was a recognized and worked architecture. On its own it adds little; as context for the Miles and Cannon disclosures it removes any argument that electrode-mounted biochemistry was an untrodden path.

3.5 Family-cited references (listed under "Family Cites Families (4)")

These appear against the family, and I cannot confirm from this record which office cited them or against which claim set (flagging the uncertainty explicitly):

• FR 1,479,929 A — Lab Equipment Corp, Method and apparatus for enzymatic analysis (1967-05-05)
• US 3,694,163 A — Miles Lab, Test system for the determination of substances in test fluids (1972-09-26)
• CH 524,142 A — Miles Lab, Electrochemical test arrangement and method for its production (1972-06-15)
• US 3,757,210 A — Betz Laboratories, deposition-testing system (1973-09-04)

CH 524,142 ("electrochemical test arrangement and method for its production") and US 3,694,163 are, on their titles, additional members of the same Miles electrochemical-test-system line as '681. If those documents likewise disclose reagent-bearing electrodes, they convert the relevant art from a single reference into a recognized, recurring design pattern — which is a stronger motivation argument under KSR than any single reference. I have not retrieved their texts and do not assert their contents.

3.6 Non-patent literature — and an applicant admission

Referenced in the '576 specification itself (patents.google.com/patent/US4072576/en):

The Bockris & Reddy citation is the single most damaging line in the patent for § 103 purposes. It is the applicant's own statement that the physical mechanism the invention exploits — adsorption of organic molecules at an electrode changing the electrode's electrical properties — was known in the art. Combined with the everyday fact (which the specification itself relies on in FIG. 5, plotting coverage as 1/C_s) that the electrode's series capacitance is a monotonic function of the adsorbed-layer coverage, the "inventive" step reduces to: apply a known electrical property that is known to change with adsorption to a known coated electrode. That is the definition of a predictable, expected-result substitution.

---

4. Grounds of rejection

Ground 1 (primary) — Bofors '896 in view of Miles '681; further in view of Cannon '534

Covers claims 1, 2, 3, 5, 6, 7, 10, 11, 12, 13, 15 (and, with Rothen, claim 4).

Rationale. '896 supplies every chemical limitation of claims 6 and 7 — the enzyme class, the substrate genus, and the express contemplation of inhibitor/antienzyme studies. '681 supplies the apparatus architecture and measurement logic of claim 1: electrodes with reagent immobilized at the surface, a sample-contacting step, a background/control channel, and an output of Δ and Δ/Δt. Cannon '534 supplies the specific combination of platinum electrodes with an enzymatic hydrolysis reaction, read as a function of time, together with the express motivation to abandon colorimetry because of optical interference.

Motivation, stated affirmatively (not inferred):

• Same problem, same field. Both '896 and '576 begin from the same complaint — chromophoric/optical assays are insensitive, slow, imprecise, and require large amounts of biological material. '896's own "objects" are the problem '576 purports to solve. Under Graham/KSR, a reference that frames the deficiency the applicant purports to cure is the strongest possible motivation evidence.
• Turbidity. Cannon '534 already announces that the electrical route "is not interfered with by extraneous colored solutions" — precisely the whole-blood problem '576 identifies.
• Expected success. Bockris & Reddy (cited by the applicant) makes the adsorption→electrical-property link known; Miles '681 makes the electrode-mounted-reagent→electrical readout link known; Cannon makes the enzyme-hydrolysis→electrical-signal link known. The remaining step — selecting capacitance among the electrode's known electrical properties — is a choice among a finite set of known, predictable alternatives with no asserted difference in kind.
• Simplicity. Both Cannon and Miles are motivated by removing operator burden (manual adjustment, reference half-cells, linearity assumptions). '576's own purpose statement — "a simple method" — is the same objective.

Anticipated objection and answer. The applicant will say Miles '681 measures conductivity, not capacitance, and puts the enzyme (not the substrate) on the electrode. Answer: (i) claim 1 does not exclude the mirror-image arrangement, and the direction of the reagent/analyte placement is a design choice with no asserted consequence; (ii) conductivity and capacitance are the two canonical components of electrode impedance, both routinely extracted from the same AC bridge measurement the patent itself uses (claim 5) — "[t]he normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of [parameters] is the optimum combination," In re Peterson, 315 F.3d 1325, 1330 (Fed. Cir. 2003).

Ground 2 — Cannon '534 in view of Bockris & Reddy (optionally with Rothen and Gough & Andrade)

Covers claims 1, 3, 5, 10, 11, 13.

Rationale. Cannon discloses platinum electrodes in an enzyme/substrate solution with a time-differentiated electrical readout for activity. Bockris & Reddy supplies the missing teaching that organic molecules adsorbing on an electrode change the electrode's electrical properties — including, as a matter of the established double-layer model, its capacitance. Rothen supplies the solid-liquid-interface layer-growth paradigm and its quantification by measuring the layer. Gough & Andrade supplies the enzyme-electrode framework.

Motivation. Cannon's DC depolarization measurement is a potential measurement, and Cannon itself requires a reference half-cell ("a half cell or a reference electrode") and close temperature control — both extra burdens. A POSA seeking to simplify would naturally move to an AC impedance/bridge determination of the electrode's double-layer capacitance, which requires no reference electrode, is nondestructive, and — per Bockris & Reddy — responds to adsorbed organic layers. That is a finite, known set of alternatives with an articulated reason to prefer the substitute, which is the KSR "predictable variation" posture.

Ground 3 — Rothen in view of Bockris & Reddy (with '896 in the enzyme sub-embodiments)

Covers claims 3, 4, 8, 9 (and claim 1's binding-pair species).

Rationale. Rothen — cited by the applicant — discloses exactly the substrate-layer-change phenomenon of claims 3 and 4: antigens adsorbed at a solid–liquid interface, antibodies coupled to them, layer thickness changing, the change quantified. It also discloses the substantive limitation of claim 4 (binding increases layer thickness). Bockris & Reddy supplies the electrical-property change on adsorption. The combination substitutes an impedance bridge for an ellipsometer.

Motivation. This is the patent's own argument inverted: the specification uses Rothen as the problem ("a rather complicated and expensive apparatus is required") and proposes capacitance as the solution. A reference that discloses a measurable interfacial-layer change and a known electrode property that varies with interfacial layer mass provides a POSA with both the reason and the capability to substitute the electrical measurement for the optical one. Claim 8's inhibitor embodiment is additionally supported by '896's express recitation of "antienzymes and enzyme inhibitors."

Ground 4 — Single-reference ground: '896 as to claim 7 (and claim 6)

Claim 7's Markush group is, comparing the two texts element-by-element, a subgenus of the '896 genus: '896 permits n = 2, 3, or 4 and '576 claim 7 restricts n to 3 or 4; '896's R¹–R⁵ definitions map onto claim 7's R¹–R⁵ (with '896's "4-aminomethyl-cyclohexylcarbonyl"/"4-amino ethyl-cyclohexyl-carbonyl" wording differences that appear to be the same substituent transcribed inconsistently between the two documents — I flag this as a textual discrepancy rather than assert identity). No unexpected property is ascribed in the '576 specification to the n = 3/4 selection. Under In re Peterson and In re Aller, 220 F.2d 454, 456 (CCPA 1955) ("where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation"), the claim-7 subgenus is an obvious selection. This is the strongest single-reference attack on the patent, because it does not depend on any apparatus combination at all.

Ground 5 — Optimization grounds: claims 14 and 16

• Claim 14 (monomolecular-layer coating). The specification says only that a monolayer "is presumably adsorbed." Its own FIG. 5 is presented as an empirical coverage-vs-concentration curve. Absent a demonstration that monolayer coverage produces a result "different in kind and not merely in degree" (Aller), this is optimization.
• Claim 16 (surface not entirely saturated). The specification states: "Experiments have indicated that the substrate shall not entirely saturate the surface, for an optimum detection efficiency," and describes an "optimum in sensitivity ... in the presence of a certain amount of added peptide." Under In re Boesch, 617 F.2d 272, 276 (CCPA 1980), "discovery of an optimum value of a result effective variable ... is ordinarily within the skill of the art." Surface coverage was plainly recognized as a result-effective variable by the applicant's own account of the Bockris & Reddy adsorption literature and by FIG. 5. Contrast In re Antonie, 559 F.2d 618, 620 (CCPA 1977), where the optimized parameter was not recognized as result-effective — that escape hatch is not available here, because the relationship between adsorbed amount and electrode electrical property is exactly what the cited literature establishes.

---

5. Secondary considerations / rebuttal — where the patent retains genuine force

I am not going to write a one-sided rejection. The following are real counterweights:

1. No express capacitance teaching. None of the four cited U.S. patents, and none of the NPL items as characterized in the specification, discloses or suggests measuring capacitance across substrate-coated electrodes. The gap is real. If the applicant can show that conductivity/potential measurements of the same system were tried and did not yield a usable signal while capacitance did, that would be probative of nonobviousness of the selection even where all components are known.
2. A different physical mechanism. Miles '681's signal arises from the ionic conductivity of the medium/matrix as the reaction proceeds; '576's arises from the mass of adsorbed substrate on the electrode surface being consumed. That is a genuinely different transduction physics. The counter to this is that the point of novelty is nonetheless a substitution of one known electrode property for another, and that the specification's own discussion of optimum surface coverage shows the difference was exploited by routine adjustment rather than by unpredictable discovery.
3. The "optimum concentration" finding. The specification reports an optimum in sensitivity at an intermediate added-peptide concentration (FIG. 5), reasoning it out from competing effects. This is the patent's best technical story, but it is presented as a reasoned prediction confirmed by "measurements [that] also indicate that such an optimum exists" — the hallmark of routine experimentation rather than an unexpected result.
4. Claim 9 (receptors for hormones) is the weakest prima facie case. Nothing in the cited art discloses a receptor-hormone binding read out by an electrode-adsorption measurement. If any claim survives, it is likely claim 9 — and it survives on the absence of art, not on any technical contribution described in the specification (the specification offers no data for it at all).
5. No secondary-consideration record is available to me. I found no evidence in the record of commercial success, long-felt need, or copying bearing a nexus to these claims. The current assignee is listed as Phadia AB (successor in the Kabi line), but I have not verified any nexus between that corporate lineage's commercial products and the '576 claims. Absent nexus evidence (In re Huang, 100 F.3d 135, 140 (Fed. Cir. 1996)), commercial success would not carry weight.
6. Teaching away: none found. Nothing in '896, '681, '534, '255, or the NPL items discourages an electrical readout; to the contrary, '896's stated deficiencies and Cannon's colorimetric criticisms push toward it. Under In re Gurley, 27 F.3d 551, 553 (Fed. Cir. 1994), no teaching-away argument is available.
7. The "mechanism" limitation is not a patentable weight-carrier. Claim 1's closing functional language ("due to a change in the amount of biochemically uneffected substrate coated on said electrodes") recites a mechanism. Under In re Papesch, 315 F.2d 381 (CCPA 1963), a claim's properties are part of the invention as a whole — but where the property is the inherent and known consequence of a known physical arrangement (per Bockris & Reddy), it does not distinguish.

---

6. Claim-by-claim assessment

Overall: claims 1–8 and 10–13 present a strong prima facie case; claims 14 and 16 are optimization cases that turn on evidence; claim 9 is the only claim I would expect to survive on the cited art alone.

---

7. Confidence and limitations

• High confidence in the substance of US 3,275,534 (retrieved text), US 3,635,681 (retrieved text), and US 3,884,896 (retrieved text), as set out above, including the verbatim quotations.
• Moderate confidence in Beckman '255: I retrieved its bibliographic record and abstract-level description, but not its full specification text.
• Unverified: the four "Family Cites Families" documents (FR 1,479,929; US 3,694,163; CH 524,142; US 3,757,210). I have characterized them from titles only and expressly flag that I do not know which office cited them or their precise disclosures.
• Unverified independently: the Rothen, Gough & Andrade, Lawrence & Moores, and Bockris & Reddy items. My characterizations of their content are drawn from the '576 specification's own descriptions of them, which is itself significant — those descriptions are applicant admissions about the state of the art, and are usable as such regardless of whether I retrieved the originals.
• Legal citations: Graham, KSR, Antonie (559 F.2d 618, CCPA 1977), Aller (220 F.2d 454, CCPA 1955), Boesch (617 F.2d 272, CCPA 1980), Peterson (315 F.3d 1325, Fed. Cir. 2003), Gurley (27 F.3d 551, Fed. Cir. 1994), Papesch (315 F.2d 381, CCPA 1963), and Huang (100 F.3d 135, Fed. Cir. 1996) are cited from the sources retrieved above and my own knowledge. I did not independently retrieve the full text of Aller or Papesch in this session; a formal opinion should Shepardize/KeyCite before filing.
• A live-prosecution caveat: because this is a validity analysis of an issued, long-expired patent rather than a pending rejection, the burden framework differs. In litigation, the challenger bears clear-and-convincing; before the PTO, preponderance. This patent expired 1995-02-07 and, per the earlier section, is not assertable.

Bottom line: On the art cited on this page, I would expect claims 1–8 and 10–13 to be held invalid under pre-AIA § 103, with claim 7 being the least defensible (a bare subgenus of the '896 genus) and claim 1 being defensible only if the applicant produced real evidence that the substitution of capacitance for conductivity, potential, and ellipsometric thickness measurement was nonobvious in result — which the specification, on its face, does not supply.